drugset / Trial / NCT03446209

Tocilizumab for the Treatment of Familial Mediterranean Fever

NCT03446209

Phase 2 Completed 30 enrolled University Hospital Tuebingen
RandomizedParallel-groupDouble-blindTreatment

Summary

Adult patients with Familial Mediterranean Fever, who have active disease

Timeline

Start
2018-04-23
Primary completion
2020-10-30
Completion
2020-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody Intravenous